Аннотация:According to STRAW+10 we use such clinical and biochemical markers as amenorrhea, FSH and AMH levels, and number of ovarian follicles to evaluate a stage of reproductive aging. It is unknown how to evaluate reproductive aging in young women with central hypogonadism which is associated with empty sella turcica syndrome, pituitary lesions or genetic disorders. A persistent amenorrhea and very low FSH levels are not valid markers for reproductive staging in these women. Compared to healthy women of similar age, untreated female patients with central hypogonadism have significantly higher rate of increased body mass, dyslipidemia, osteopenia and urogenital disorders, as we generally observe in women of postmenopausal age. Low levels of both estrogens and androgens are characteristic for these women. Taking into account all these clinical and hormonal features of central hypogonadism it is obvious that health condition of these women is similar to postmenopausal women independently of their chronological age. Termination of menstrual function due to irreversible central hypogonadism should be considered as "a central menopause".